Metal Hypothesis for Alzheimer's, Huntington and Other

Metal Hypothesis for Alzheimer's, Huntington and Other
Neurodegenerative Diseases Declared Promising Therapeutic Strategy by
Scientists at New York Academy of Sciences Symposium 
MELBOURNE, AUSTRALIA -- (Marketwire) -- 12/05/12 --   Prana
Biotechnology (NASDAQ: PRAN) (ASX: PBT) today announced that leading
scientists discussing the Metal Hypothesis at the New York Academy of
Science on November 29th at a symposium titled "Targeting Metals in
Alzheimer's and Other Neurodegenerative Diseases," highlighted the
promise that therapies like Prana's PBT2 could offer for sufferers of
neurodegenerative diseases.   
This symposium examined findings that have led to the discovery of
small molecules designed to restore the balance of transition metals
in the brain that are critical for normal neuronal function, that
reduce the accumulation of aggregated target proteins associated with
disease, and that could have a disease-modifying effect.   
Dr. Rudy Tanzi, the Joseph P. and Rose F. Kennedy Professor of
Neurology at Harvard University and Prana's Chief Scientific Advisor,
said, "Researchers are increasingly focusing on the role of metals in
neurodegenerative disease, providing data that promotes optimism for
the outcome of Prana's trials. As we learn more about the genetics of
Alzheimer's disease it increasingly appears that the disease is
triggered by the excessive accumulation of the amyloid beta protein
in the brain. Prana's therapeutic strategy for treating
neurodegenerative disease involves a highly differentiated mechanism
of action as an anti-beta-amyloid drug therapy." Rather than simply
trying to stop production of all native amyloid beta protein, PBT2
(i) prevents the metal dependent conversion of amyloid beta protein
into oligomers that are toxic to synapses and (ii) restores normal
brain metal distribution that is essential for neuronal health and
synaptic function.  
Dr. Steven M. Hersch, of Massachusetts General Hospital and Harvard
Medical School said, "Transition metals, especially iron and copper,
have been implicated in the pathogenesis of Huntington disease.
Copper may directly modulate the toxicity of the huntingtin protein
(Htt) while iron accumulation in response to neurodegeneration likely
potentiates the damage to the central nervous system, making both
metals potential therapeutic targets. PBT2 is the first clinical
candidate that modulates Htt directly."  
Dr. Dan Tardiff, of the Whitehead Institute for Biomedical Research,
said, "We have screened multiple validated yeast cells of
proteotoxicity and identified numerous compounds that restore protein
homeostasis and rescue cells from death. We have several compounds
that rescue cell death through altering metal homeostasis. Though it
is not clear the precise mechanism in some cases, it is becoming more
apparent that, along with molecules like PBT2, targeting metals may
ultimately be a productive therapeutic strategy in several
neurodegenerative diseases." 
The presentations explored the causative events leading to the
neuropathology that drives Alzheimer's disease, Parkinson's disease
and Huntington disease. Dr. Robert Cherny of The Florey Institute of
Neuroscience and Mental Health, Melbourne, and Prana's Head of
Research, said, "We have been investigating the therapeutic potential
of drugs which act to inhibit pathological metal-protein interactions
and promote neuronal function by restoring metal homeostasis. We
believe that cognition can be improved significantly with drugs like
PBT2." 
About Prana Biotechnology Limited
 Prana Biotechnology was
established to commercialize research into age-related
neurodegenerative disorders. The Company was incorporated in 1997 and
listed on the Australian Securities Exchange in March 2000 and listed
on NASDAQ in September 2002. Researchers at prominent international
institutions including The University of Melbourne, The Mental Health
Research Institute (Melbourne) and Massachusetts General Hospital, a
teaching hospital of Harvard Medical School, contributed to the
discovery of Prana's technology.  
For further information please visit the Company's web site at
www.pranabio.com. 
About the New York Academy of Sciences
 The New York Academy of
Sciences is an independent, not-for-profit organization committed to
advancing science, technology, and society worldwide since 1817. With
25,000 members in 140 countries, the Academy is creating a global
community of science for the benefit of humanity. The Academy's core
mission is to advance scientific knowledge, positively impact the
major global challenges of society with science-based solutions, and
increase the number of scientifically informed individuals in society
at large. Visit www.nyas.org for more information on the Academy.  
Forward Looking Statements 
 This press release contains
"forward-looking statements" within the meaning of section 27A of the
Securities Act of 1933 and section 21E of the Securities Exchange Act
of 1934. The Company has tried to identify such forward-looking
statements by use of such words as "expects," "intends," "hopes,"
"anticipates," "believes," "could," "may," "evidences" and
"estimates," and other similar expressions, but these words are not
the exclusive means of identifying such statements. Such statements
include, but are not limited to any statements relating to the
Company's drug development program, including, but not limited to the
initiation, progress and outcomes of clinical trials of the Company's
drug development program, including, but not limited to, PBT2, and
any other statements that are not historical facts. Such statements
involve risks and uncertainties, including, but not limited to, those
risks and uncertainties relating to the difficulties or delays in
financing, development, testing, regulatory approval, production and
marketing of the Company's drug components, including, but not
limited to, PBT2, the ability of the Company to procure additional
future sources of financing, unexpected adverse side effects or
inadequate therapeutic efficacy of the Company's drug compounds,
including, but not limited to, PBT2, that could slow or prevent
products coming to market, the uncertainty of patent protection for
the Company's intellectual property or trade secrets, including, but
not limited to, the intellectual property relating to PBT2, and other
risks detailed from time to time in the filings the Company makes
with Securities and Exchange Commission including its annual reports
on Form 20-F and its reports on Form 6-K. Such statements are based
on management's current expectations, but actual results may differ
materially due to various factions including those risks and
uncertainties mentioned or referred to in this press release.
Accordingly, you should not rely on those forward-looking statements
as a prediction of actual future results. 
Contacts:
Australia
Prana Biotechnology
+61 3 9349 4906 
US
Leslie Wolf-Creutzfeldt
T: 646-284-9472
E: leslie.wolf-creutzfeldt@grayling.com 
 
 
Press spacebar to pause and continue. Press esc to stop.